Eximias enrolls Thymitaq Phase III

Eximias (Berwyn, Penn.) completed enrollment of 446 patients in the open-label, international, Phase III ETHECC trial of Thymitaq nolatrexed (formerly AG337) to treat unresectable hepatocellular carci...